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Purpose: Mitomycin C (MMC) is widely used in treatment of non-muscle invasive
bladder cancer at a 1 mg/mL concentration, by intravesical instillation. MMC is also
used as an ophthalmic procedure in glaucoma care mostly with 0.2 mg/mL
concentration. To accelerate syringes provision, it could be interesting to demonstrate
the stability of the drug, in order to be able to prepare the chemotherapeutic drug
several hours before the chemotherapy administration.
Methods: A stability indicating HPLC-UV method was developed and validated
according to the ICH guidelines. Concentrations of the MMC stored at 25 °C and 60 %
of relative humidity and protected from light in polypropylene syringes (1 mg/mL and
0.2 mg/mL) or glass vials (1 mg/mL) were evaluated for 96 h and compared to the
initial observed concentrations.
Results: MMC stability was demonstrated in syringes and glass vials at 1 mg/mL only
for 8 h in water for injections and for 10 h at 0.2 mg/mL in 0.9 % sodium chloride
solutions, because relative concentrations (95 % confidence interval of the mean of 3
samples) were systematically over 90 % of the initial concentrations. After 96 h the
relative concentrations were found below 80 % as compared to initial concentrations,
thus indicating instability of these solutions. Degradation products were observed and
remained below 3 %.
Conclusion: This study confirms that MMC solutions for ophthalmic application at 0.2
mg/mL or vesical instillation at 1 mg/mL have to be formulated extemporaneously to
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